| Nicotine decreases food intake through activation of POMC neurons. | |
| | |
MedLine Citation:
|
PMID: 21659607 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Smoking decreases appetite, and smokers often report that they smoke to control their weight. Understanding the neurobiological mechanisms underlying the anorexic effects of smoking would facilitate the development of novel treatments to help with smoking cessation and to prevent or treat obesity. By using a combination of pharmacological, molecular genetic, electrophysiological, and feeding studies, we found that activation of hypothalamic α3β4 nicotinic acetylcholine receptors leads to activation of pro-opiomelanocortin (POMC) neurons. POMC neurons and subsequent activation of melanocortin 4 receptors were critical for nicotinic-induced decreases in food intake in mice. This study demonstrates that nicotine decreases food intake and body weight by influencing the hypothalamic melanocortin system and identifies critical molecular and synaptic mechanisms involved in nicotine-induced decreases in appetite. |
| | |
Authors:
|
Yann S Mineur; Alfonso Abizaid; Yan Rao; Ramiro Salas; Ralph J DiLeone; Daniela Gündisch; Sabrina Diano; Mariella De Biasi; Tamas L Horvath; Xiao-Bing Gao; Marina R Picciotto |
Related Documents
:
|
12709477 - Genetically modified soybeans and food allergies. 11964687 - The role of plant panallergens in sensitization to natural rubber latex. 16784017 - Exotic pets are new allergenic sources: allergy to iguana. 8939157 - Identification of a 60 kd cross-reactive allergen in pollen and plant-derived food. 20627107 - Balancing organization and flexibility in foraging dynamics. 10181517 - Orthopedic devices: classification and reclassification of pedicle screw spinal systems... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Science (New York, N.Y.) Volume: 332 ISSN: 1095-9203 ISO Abbreviation: Science Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-06-10 Completed Date: 2011-06-21 Revised Date: 2013-03-08 |
Medline Journal Info:
|
Nlm Unique ID: 0404511 Medline TA: Science Country: United States |
Other Details:
|
Languages: eng Pagination: 1330-2 Citation Subset: IM |
Affiliation:
|
Department of Psychiatry, Yale University School of Medicine, 34 Park Street, Third Floor Research, New Haven, CT 06508, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alkaloids
/
metabolism Animals Azocines / metabolism Eating / drug effects* Ganglionic Stimulants / pharmacology* Male Melanocortins / metabolism Mice Mice, Inbred C57BL Mice, Knockout Neurons / drug effects, metabolism Nicotine / pharmacology* Nicotinic Agonists / pharmacology Pro-Opiomelanocortin / metabolism* Quinolizines / metabolism Receptors, Nicotinic / metabolism |
| Grant Support | |
ID/Acronym/Agency:
|
AA15632/AA/NIAAA NIH HHS; DA00436/DA/NIDA NIH HHS; DA017173/DA/NIDA NIH HHS; DA14241/DA/NIDA NIH HHS; DK070039/DK/NIDDK NIH HHS; DK070723/DK/NIDDK NIH HHS; DK080000/DK/NIDDK NIH HHS; DP1 OD006850-02/OD/NIH HHS; K02 DA000436-10/DA/NIDA NIH HHS; OD006850/OD/NIH HHS; P20 RR016467-10/RR/NCRR NIH HHS; P50 AA015632-10/AA/NIAAA NIH HHS; R01 DA014241/DA/NIDA NIH HHS; R01 DA014241-10/DA/NIDA NIH HHS; R01 DA017173-07/DA/NIDA NIH HHS; R01 DK070039-04/DK/NIDDK NIH HHS; R01 DK070723-05/DK/NIDDK NIH HHS; R01 DK070723-05S2/DK/NIDDK NIH HHS; R01 DK080000-04/DK/NIDDK NIH HHS; RR016467/RR/NCRR NIH HHS; U19 CA148127/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Alkaloids; 0/Azocines; 0/Ganglionic Stimulants; 0/Melanocortins; 0/Nicotinic Agonists; 0/Quinolizines; 0/Receptors, Nicotinic; 0/nicotinic receptor alpha3beta4; 485-35-8/cytisine; 54-11-5/Nicotine; 66796-54-1/Pro-Opiomelanocortin |
| Comments/Corrections | |
Comment In:
|
Cell Metab. 2011 Aug 3;14(2):145-7
[PMID:
21803282
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Adaptation and evolutionary rescue in metapopulations experiencing environmental deterioration.
Next Document: Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.